

BOARD PAPER - NHS ENGLAND

Title: New Congenital Heart Disease (CHD) Review update

Clearance: Ian Dodge, National Director: Commissioning Strategy
Professor Sir Malcolm Grant, Chair

Purpose of paper:

- To inform the board of the progress of the new CHD review.

Actions required by the Board:

The Board is asked to:

- note the progress of the new congenital heart disease review.

Update from the Board Task and Finish Group on the new Congenital Heart Disease (CHD) review

Background

1. The purpose of this paper is to provide an update to the NHS England Board on the progress of the new congenital heart disease review, following discussion at the Board's task and finish group (the "Group") on 24 November.

Board Task and Finish Group – meeting on 24 November

2. The Group received an update on the consultation on draft service standards, and discussed the programme plan, commissioning challenges and the associated handover plan. The Group also received updates on Terms of Reference and discussed how the recommendations of the recent Verita report (October 2014) would be actioned to ensure lessons were learnt for the new CHD review.
3. The group were advised that the closing date for the consultation on standards is 8 December. Following consultation the responses would be analysed by an independent third party organisation who would report on the findings, enabling NHS England to then prepare a response and to make any changes to the draft standards. The target date for this to be completed is end March 2015, which requires the various governance requirements to have been satisfied. There is work underway to refine the governance process for all specialised service changes.
4. The group were advised on the engagement undertaken to date; and noted that some materials have now been translated (in response to local government feedback) in the following languages: Gujarati, Hindu, Polish, Punjabi, Tamil, Urdu and Welsh.

Recommendations

5. The Board is asked to note the Task and Finish Group's report on progress of the new congenital heart disease review.

Ian Dodge
National Director: Commissioning Strategy